Intestinal Flora Sequencing for Nasopharyngeal Carcinoma
Intestinal Flora Disruption and a Novel Intestinal Biomarker Associated With Nasopharyngeal Carcinoma
1 other identifier
observational
568
1 country
1
Brief Summary
This study investigated the correlation between the changes in the intestinal flora and NPC by an examination of the intestinal flora and multiple clinical indicators of the blood of 8 carefully screened patients of familial NPC, 24 patients of sporadic NPC and 27 healthy controls and a comparison of the differences in their intestinal flora structures and biological functions. By analyzing the function of the intestinal floras of NPC patients, we aimed to provide a better biological marker for patients with familial and sporadic NPC and constructed a disease prediction model for high-risk populations.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2018
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
May 30, 2019
CompletedFirst Submitted
Initial submission to the registry
September 17, 2019
CompletedFirst Posted
Study publicly available on registry
September 19, 2019
CompletedSeptember 19, 2019
September 1, 2018
5 months
September 17, 2019
September 17, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
family NPC patients
NPC patients with a first degree NPC family history
through study completion, an average of 1 year
sporadic NPC patients
NPC patients without any tumor family history
through study completion, an average of 1 year
Study Arms (2)
Nasopharyngeal carcinoma(NPC)
The patients (1) were diagnosed with NPC; 2)18\< Age \<75.
Health adults
(1) 18\< Age \<75, and Han Chinese residents living in Hunan more than 3 years. (2) Health examination population who physical examination, assistant examination and serological examination were normal; None of the patients had rhinitis or used any antibiotics during the three months last 3 months.
Eligibility Criteria
We recruited 481 NPC patients and staged their tumor status with the AJCC 7th edition staging criteria,at the same time, 87 healthy volunteers were recruited.
You may qualify if:
- NPC patients with a first degree family history of NPC
- NPC patients without any kind of tumor family history
You may not qualify if:
- Informed refusal.
- Lack of necessary tests and patient test information is not detailed
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
the Third Xiangya Hospital of Central South University
Changsha, Hunan, 410006, China
Related Publications (8)
Bei JX, Li Y, Jia WH, Feng BJ, Zhou G, Chen LZ, Feng QS, Low HQ, Zhang H, He F, Tai ES, Kang T, Liu ET, Liu J, Zeng YX. A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet. 2010 Jul;42(7):599-603. doi: 10.1038/ng.601. Epub 2010 May 30.
PMID: 20512145RESULTBhatt AP, Redinbo MR, Bultman SJ. The role of the microbiome in cancer development and therapy. CA Cancer J Clin. 2017 Jul 8;67(4):326-344. doi: 10.3322/caac.21398. Epub 2017 May 8.
PMID: 28481406RESULTBokulich NA, Kaehler BD, Rideout JR, Dillon M, Bolyen E, Knight R, Huttley GA, Gregory Caporaso J. Optimizing taxonomic classification of marker-gene amplicon sequences with QIIME 2's q2-feature-classifier plugin. Microbiome. 2018 May 17;6(1):90. doi: 10.1186/s40168-018-0470-z.
PMID: 29773078RESULTBray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
PMID: 30207593RESULTChung H, Pamp SJ, Hill JA, Surana NK, Edelman SM, Troy EB, Reading NC, Villablanca EJ, Wang S, Mora JR, Umesaki Y, Mathis D, Benoist C, Relman DA, Kasper DL. Gut immune maturation depends on colonization with a host-specific microbiota. Cell. 2012 Jun 22;149(7):1578-93. doi: 10.1016/j.cell.2012.04.037.
PMID: 22726443RESULTEscobar JS, Klotz B, Valdes BE, Agudelo GM. The gut microbiota of Colombians differs from that of Americans, Europeans and Asians. BMC Microbiol. 2014 Dec 14;14:311. doi: 10.1186/s12866-014-0311-6.
PMID: 25495462RESULTFerlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pineros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019 Apr 15;144(8):1941-1953. doi: 10.1002/ijc.31937. Epub 2018 Dec 6.
PMID: 30350310RESULTGoodrich JK, Waters JL, Poole AC, Sutter JL, Koren O, Blekhman R, Beaumont M, Van Treuren W, Knight R, Bell JT, Spector TD, Clark AG, Ley RE. Human genetics shape the gut microbiome. Cell. 2014 Nov 6;159(4):789-99. doi: 10.1016/j.cell.2014.09.053.
PMID: 25417156RESULT
Biospecimen
The faeces and the sera of the recruited participants
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 17, 2019
First Posted
September 19, 2019
Study Start
August 1, 2018
Primary Completion
December 31, 2018
Study Completion
May 30, 2019
Last Updated
September 19, 2019
Record last verified: 2018-09
Data Sharing
- IPD Sharing
- Will not share